Now showing items 1-5 of 5

    • Cell contact, prostaglandin e2and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of cd4+cd25highforkhead box p3+regulatory t cells 

      English, K.; Ryan, J. M.; Tobin, L.; Murphy, M. J.; Barry, F. P.; Mahon, B. P. (Wiley-Blackwell, 2009-04-01)
      Adult human mesenchymal stromal or stem cells (MSC) can differentiate into a variety of cell types and are candidate cellular therapeutics in regenerative medicine. Surprisingly, these cells also display multiple potent ...
    • Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? 

      Griffin, Matthew D.; Elliman, Stephen J.; Cahill, Emer; English, Karen; Ceredig, Rhodri; Ritter, Thomas (Wiley-Blackwell, 2013-10-01)
      Mesenchymal stromal (stem) cells (MSCs) continue to be a strong area of focus for academic- and industry-based researchers who share the goal of expanding their therapeutic use for diverse inflammatory and immune-mediated ...
    • Immunogenicity of allogeneic mesenchymal stem cells 

      Schu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (Wiley-Blackwell, 2012-08-23)
      Mesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether ...
    • Immunological aspects of allogeneic mesenchymal stem cell therapies 

      Griffin, Matthew D.; Ritter, Thomas; Mahon, Bernard P. (Mary Ann Liebert Inc, 2010-12-01)
      Allogeneic mesenchymal stem or stromal cells (MSCs) are proposed as cell therapies for degenerative, inflammatory, and autoimmune diseases. The feasibility of allogeneic MSC therapies rests heavily on the concept that these ...
    • Minimum information about t regulatory cells: a step toward reproducibility and standardization 

      Fuchs, Anke; Gliwiński, Mateusz; Grageda, Nathali; Spiering, Rachel; Abbas, Abul K.; Appel, Silke; Bacchetta, Rosa; Battaglia, Manuela; Berglund, David; Blazar, Bruce; Bluestone, Jeffrey A.; Bornhäuser, Martin; ten Brinke, Anja; Brusko, Todd M.; Cools, Nathalie; Cuturi, Maria Cristina; Geissler, Edward; Giannoukakis, Nick; Gołab, Karolina; Hafler, David A.; van Ham, S. Marieke; Hester, Joanna; Hippen, Keli; Di Ianni, Mauro; Ilic, Natasa; Isaacs, John; Issa, Fadi; Iwaszkiewicz-Grześ, Dorota; Jaeckel, Elmar; Joosten, Irma; Klatzmann, David; Koenen, Hans; van Kooten, Cees; Korsgren, Olle; Kretschmer, Karsten; Levings, Megan; Marek-Trzonkowska, Natalia Maria; Martinez-Llordella, Marc; Miljkovic, Djordje; Mills, Kingston H.G.; Miranda, Joana P.; Piccirillo, Ciriaco A.; Putnam, Amy L.; Ritter, Thomas; Roncarolo, Maria Grazia; Sakaguchi, Shimon; Sánchez-Ramón, Silvia; Sawitzki, Birgit; Sofronic-Milosavljevic, Ljiljana; Sykes, Megan; Tang, Qizhi; Vives-Pi, Marta; Waldmann, Herman; Witkowski, Piotr; Wood, Kathryn J.; Gregori, Silvia; Hilkens, Catharien M. U.; Lombardi, Giovanna; Lord, Phillip; Martinez-Caceres, Eva M.; Trzonkowski, Piotr (Frontiers Media SA, 2018-01-15)
      Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing ...